Insider transactions

EDGAR

Compass Therapeutics, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-15.

Open-market purchases (code P)
4 transactions, 62,500 shares
Sum of shares × price per share: 96,850
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–25 of 25

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-01 Filed 2026-10-02Lerner Neil Officer: Chief Accounting Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)20,0000.92
18,400

Derived: shares × price per share. Exact value 18400.00.

420,000Direct (D) No
F1
  • F1 62,500 of the shares represents unvested restricted stock units (RSU) granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.
Open filing 0001171843-26-006349 Read from the filing’s XML Dispute this row
2026-09-24 Filed 2026-09-25Lerner Neil Officer: Chief Accounting Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)2,5001.14
2,850

Derived: shares × price per share. Exact value 2850.00.

400,000Direct (D) No
F1
  • F1 62,500 of the shares represents unvested restricted stock units (RSU) granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.
Open filing 0001171843-26-006235 Read from the filing’s XML Dispute this row
2026-04-29 Filed 2026-04-30Lerner Neil Officer: Chief Accounting Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)15,0001.89
28,350

Derived: shares × price per share. Exact value 28350.00.

397,500Direct (D) No
F1
  • F1 62,500 of the shares represents unvested restricted stock units (RSU) granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.
Open filing 0001171843-26-002894 Read from the filing’s XML Dispute this row
2026-04-29 Filed 2026-04-30Anderman Jonathan Officer: General Counsel
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)25,0001.89
47,250

Derived: shares × price per share. Exact value 47250.00.

196,000Direct (D) No
F1
  • F1 150,000 of the shares represents unvested restricted stock units (RSU) granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.
Open filing 0001171843-26-002893 Read from the filing’s XML Dispute this row
2026-04-29 Filed 2026-04-29Anderman Jonathan Officer: General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,0001.89
47,250

Derived: shares × price per share. Exact value 47250.00.

196,000Direct (D) No
F1
  • F1 150,000 of the shares represents unvested restricted stock units (RSU) granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.
Open filing 0001171843-26-002840 Read from the filing’s XML Dispute this row
2026-04-29 Filed 2026-04-29Lerner Neil Officer: Chief Accounting Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)15,0001.89
28,350

Derived: shares × price per share. Exact value 28350.00.

397,500Direct (D) No
F1
  • F1 62,500 of the shares represents unvested restricted stock units (RSU) granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.
Open filing 0001171843-26-002834 Read from the filing’s XML Dispute this row
2026-02-08 Filed 2026-02-10Schuetz Thomas J. Director · Officer: CHIEF EXECUTIVE OFFICER
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)36,6876.52
239,199.24

Derived: shares × price per share. Exact value 239199.24.

6,603,336Direct (D) No
F1, F2
  • F1 Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs).
  • F2 125,000 of the shares represent unvested restricted stock units (RSU) granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 318,750 of the shares represent unvested restricted stock units (RSU) granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units (RSU) granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.
Open filing 0001171843-26-000722 Read from the filing’s XML Dispute this row
2026-01-09 Filed 2026-01-12Schuetz Thomas J. Director · Officer: CHIEF EXECUTIVE OFFICER
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)46,7775.35
250,256.95

Derived: shares × price per share. Exact value 250256.95.

6,640,023Direct (D) No
F1, F2
  • F1 Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs).
  • F2 250,000 of the shares represent unvested restricted stock units (RSU) granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 318,750 of the shares represent unvested restricted stock units (RSU) granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units (RSU) granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.
Open filing 0001171843-26-000205 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05GRAY MARY ANN Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (90,000) — exercise price 5.17
Acquired (A)90,0000—90,000Direct (D) No
F1
  • F1 This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders.
Open filing 0001171843-26-000055 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Shin Barry Officer: CFO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)125,0005.17
646,250

Derived: shares × price per share. Exact value 646250.00.

525,000Direct (D) No
F1, F2
  • F1 Represents restricted stock units (RSU) granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first vesting on January 2, 2027.
  • F2 300,000 of the shares represents unvested restricted stock units (RSU) granted on December 9, 2024. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on December 9, 2025. 125,000 of the shares represents unvested restricted stock units (RSU) granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.
Open filing 0001171843-26-000062 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Shin Barry Officer: CFO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (670,000) — exercise price 5.17
Acquired (A)670,0000—670,000Direct (D) No
F3
  • F3 The options vest over 48 substantially equal monthly installments starting February 2, 2026.
Open filing 0001171843-26-000062 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Schuetz Thomas J. Director · Officer: CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)250,0005.17
1,292,500

Derived: shares × price per share. Exact value 1292500.00.

6,686,800Direct (D) No
F1, F2
  • F1 Represents restricted stock units (RSU) granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first vesting on January 2, 2027.
  • F2 250,000 of the shares represent unvested restricted stock units (RSU) granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested restricted stock units (RSU) granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units (RSU) granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.
Open filing 0001171843-26-000060 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Schuetz Thomas J. Director · Officer: CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (2,000,000) — exercise price 5.17
Acquired (A)2,000,0000—2,000,000Direct (D) No
F3
  • F3 The options vest over 48 substantially equal monthly installments starting February 2, 2026.
Open filing 0001171843-26-000060 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05LINDAHL RICHARD S Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (90,000) — exercise price 5.17
Acquired (A)90,0000—90,000Direct (D) No
F1
  • F1 This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders.
Open filing 0001171843-26-000058 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Lerner Neil Officer: Chief Accounting Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)62,5005.17
323,125

Derived: shares × price per share. Exact value 323125.00.

382,500Direct (D) No
F1, F2
  • F1 Represents restricted stock units (RSU) granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first vesting on January 2, 2027.
  • F2 62,500 of the shares represents unvested restricted stock units (RSU) granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.
Open filing 0001171843-26-000056 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Lerner Neil Officer: Chief Accounting Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (435,000) — exercise price 5.17
Acquired (A)435,0000—435,000Direct (D) No
F3
  • F3 The options vest over 48 substantially equal monthly installments starting February 2, 2026.
Open filing 0001171843-26-000056 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Boylan James P Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (90,000) — exercise price 5.17
Acquired (A)90,0000—90,000Direct (D) No
F1, F2
  • F1 This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders.
  • F2 The Reporting Person is a member of Enavate Sciences, LP (Enavate). Pursuant to an agreement with Enavate, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to Enavate, which will in turn ensure that such securities or economic benefits are provided to Enavate
Open filing 0001171843-26-000054 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Prasad Arjun Officer: Chief Commercial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: STOCK OPTION (RIGHT TO BUY) — underlying COMMON STOCK (1,000,000) — exercise price 5.17
Acquired (A)1,000,0000—1,000,000Direct (D) No
F1, F2
  • F1 The options were granted pursuant to the Compass Therapeutics, Inc. 2025 Inducement Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4).
  • F2 The options will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 2, 2027, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
Open filing 0001171843-26-000059 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Sirard Cynthia Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: STOCK OPTION (RIGHT TO BUY) — underlying COMMON STOCK (1,000,000) — exercise price 5.17
Acquired (A)1,000,0000—1,000,000Direct (D) No
F1, F2
  • F1 The options were granted pursuant to the Compass Therapeutics, Inc. 2025 Inducement Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4).
  • F2 The options will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 2, 2027, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
Open filing 0001171843-26-000061 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Ferneau Philip Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (90,000) — exercise price 5.17
Acquired (A)90,0000—90,000Direct (D) No
F1
  • F1 This grant vests in full upon the earlier of (i) June 10, 2026 and (ii) the date of the next annual meeting of the Company's stockholders.
Open filing 0001171843-26-000052 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Chiniara Ellen Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (90,000) — exercise price 5.17
Acquired (A)90,0000—90,000Direct (D) No
F1
  • F1 This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders.
Open filing 0001171843-26-000057 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05GORDON CARL L Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (90,000) — exercise price 5.17
Acquired (A)90,0000—90,000Direct (D) No
F1, F2
  • F1 This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders.
  • F2 The Reporting Person is a member of OrbiMed Advisors LLC (OrbiMed Advisors). Pursuant to an agreement with OrbiMed Advisors, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and OrbiMed Capital GP V LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V-KA, LP.
Open filing 0001171843-26-000053 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Anderman Jonathan Officer: General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)150,0005.17
775,500

Derived: shares × price per share. Exact value 775500.00.

171,000Direct (D) No
F1, F2
  • F1 Represents restricted stock units (RSU) granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first vesting on January 2, 2027.
  • F2 150,000 of the shares represents unvested restricted stock units (RSU) granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.
Open filing 0001171843-26-000051 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Anderman Jonathan Officer: General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (720,000) — exercise price 5.17
Acquired (A)720,0000—720,000Direct (D) No
F3
  • F3 The options vest over 48 substantially equal monthly installments starting February 2, 2026.
Open filing 0001171843-26-000051 Read from the filing’s XML Dispute this row
2025-11-16 Filed 2025-11-18Schuetz Thomas J. Director · Officer: CHIEF EXECUTIVE OFFICER
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)44,0254.83
212,640.75

Derived: shares × price per share. Exact value 212640.75.

6,436,800Direct (D) No
F1, F2
  • F1 Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs).
  • F2 250,000 of the shares represent unvested restricted stock units (RSU) granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested restricted stock units (RSU) granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025.
Open filing 0001171843-25-007400 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
STATE STREET CORPORATION COMMON STOCK4.37,737,938.0009/30/2026 Filed 2026-11-10SCHEDULE 13GOpen filing 0000093751-26-000634 Dispute this row
Vivo Opportunity Fund Holdings, L.P. Common Stock, par value $0.0001 per share4.07,207,573.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-089989 Dispute this row
Vivo Opportunity, LLC Common Stock, par value $0.0001 per share4.07,207,573.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-089989 Dispute this row
Vivo Opportunity Cayman Fund, L.P. Common Stock, par value $0.0001 per share0.3549,487.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-089989 Dispute this row
Vivo Opportunity Cayman, LLC Common Stock, par value $0.0001 per share0.3549,487.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-089989 Dispute this row
STATE STREET CORPORATION COMMON STOCK5.59,953,653.0006/30/2026 Filed 2026-08-07SCHEDULE 13GOpen filing 0000093751-26-000440 Dispute this row
BIOTECHNOLOGY VALUE FUND L P Common Stock, $0.0001 par value per share2.34,142,020.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-001388 Dispute this row
BVF I GP LLC Common Stock, $0.0001 par value per share2.34,142,020.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-001388 Dispute this row
BIOTECHNOLOGY VALUE FUND II LP Common Stock, $0.0001 par value per share1.73,028,951.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-001388 Dispute this row
BVF II GP LLC Common Stock, $0.0001 par value per share1.73,028,951.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-001388 Dispute this row
Biotechnology Value Trading Fund OS LP Common Stock, $0.0001 par value per share0.3476,311.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-001388 Dispute this row
BVF Partners OS Ltd. Common Stock, $0.0001 par value per share0.3476,311.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-001388 Dispute this row
BVF GP HOLDINGS LLC Common Stock, $0.0001 par value per share4.07,170,971.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-001388 Dispute this row
BVF PARTNERS L P/IL Common Stock, $0.0001 par value per share4.37,764,842.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-001388 Dispute this row
BVF INC/IL Common Stock, $0.0001 par value per share4.37,764,842.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-001388 Dispute this row
LAMPERT MARK N Common Stock, $0.0001 par value per share4.37,764,842.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-001388 Dispute this row
Blackstone Annex Master Fund L.P. Common Stock, $0.0001 par value per share1.42,447,82012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-051513 Dispute this row
Spruce Street Aggregator L.P. Common Stock, $0.0001 par value per share2.13,678,36212/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-051513 Dispute this row
Blackstone Alternative Asset Management Associates LLC Common Stock, $0.0001 par value per share3.46,126,18212/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-051513 Dispute this row
Blackstone Holdings II L.P. Common Stock, $0.0001 par value per share3.46,126,18212/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-051513 Dispute this row
Blackstone Holdings I/II GP L.L.C. Common Stock, $0.0001 par value per share3.46,126,18212/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-051513 Dispute this row
Blackstone Inc. Common Stock, $0.0001 par value per share3.46,126,18212/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-051513 Dispute this row
Blackstone Group Management L.L.C. Common Stock, $0.0001 par value per share3.46,126,18212/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-051513 Dispute this row
Stephen A. Schwarzman Common Stock, $0.0001 par value per share3.46,126,18212/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-051513 Dispute this row
BlackRock, Inc. Common Stock5.29,271,64412/31/2025 Filed 2026-01-21SCHEDULE 13GOpen filing 0002012383-26-000660 Dispute this row
BIOTECHNOLOGY VALUE FUND L P Common Stock, $0.0001 par value per share2.74,673,550.0010/22/2025 Filed 2025-10-29SCHEDULE 13GOpen filing 0000921895-25-002825 Dispute this row
BVF I GP LLC Common Stock, $0.0001 par value per share2.74,673,550.0010/22/2025 Filed 2025-10-29SCHEDULE 13GOpen filing 0000921895-25-002825 Dispute this row
BIOTECHNOLOGY VALUE FUND II LP Common Stock, $0.0001 par value per share2.03,396,894.0010/22/2025 Filed 2025-10-29SCHEDULE 13GOpen filing 0000921895-25-002825 Dispute this row
BVF II GP LLC Common Stock, $0.0001 par value per share2.03,396,894.0010/22/2025 Filed 2025-10-29SCHEDULE 13GOpen filing 0000921895-25-002825 Dispute this row
Biotechnology Value Trading Fund OS LP Common Stock, $0.0001 par value per share0.3542,486.0010/22/2025 Filed 2025-10-29SCHEDULE 13GOpen filing 0000921895-25-002825 Dispute this row
BVF Partners OS Ltd. Common Stock, $0.0001 par value per share0.3542,486.0010/22/2025 Filed 2025-10-29SCHEDULE 13GOpen filing 0000921895-25-002825 Dispute this row
BVF GP HOLDINGS LLC Common Stock, $0.0001 par value per share4.78,070,444.0010/22/2025 Filed 2025-10-29SCHEDULE 13GOpen filing 0000921895-25-002825 Dispute this row
BVF PARTNERS L P/IL Common Stock, $0.0001 par value per share5.18,750,000.0010/22/2025 Filed 2025-10-29SCHEDULE 13GOpen filing 0000921895-25-002825 Dispute this row
BVF INC/IL Common Stock, $0.0001 par value per share5.18,750,000.0010/22/2025 Filed 2025-10-29SCHEDULE 13GOpen filing 0000921895-25-002825 Dispute this row
LAMPERT MARK N Common Stock, $0.0001 par value per share5.18,750,000.0010/22/2025 Filed 2025-10-29SCHEDULE 13GOpen filing 0000921895-25-002825 Dispute this row
TANG CAPITAL MANAGEMENT, LLC Common Stock, par value $0.0001 per share9.9917,176,510.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001214659-25-016688 Dispute this row
KEVIN TANG Common Stock, par value $0.0001 per share9.9917,176,510.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001214659-25-016688 Dispute this row
TANG CAPITAL PARTNERS, LP Common Stock, par value $0.0001 per share5.9810,274,944.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001214659-25-016688 Dispute this row
TANG CAPITAL PARTNERS INTERNATIONAL, LP Common Stock, par value $0.0001 per share3.245,568,566.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001214659-25-016688 Dispute this row
TANG CAPITAL PARTNERS III, INC Common Stock, par value $0.0001 per share0.58999,750.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001214659-25-016688 Dispute this row
TANG CAPITAL PARTNERS IV, INC Common Stock, par value $0.0001 per share0.19333,250.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001214659-25-016688 Dispute this row
Vivo Opportunity Fund Holdings, L.P. Common Stock, par value $0.0001 per share5.18,995,979.0009/30/2025 Filed 2025-11-14SCHEDULE 13GOpen filing 0001213900-25-111134 Dispute this row
Vivo Opportunity, LLC Common Stock, par value $0.0001 per share5.18,995,979.0009/30/2025 Filed 2025-11-14SCHEDULE 13GOpen filing 0001213900-25-111134 Dispute this row
Vivo Opportunity Cayman Fund, L.P. Common Stock, par value $0.0001 per share0.3549,487.0009/30/2025 Filed 2025-11-14SCHEDULE 13GOpen filing 0001213900-25-111134 Dispute this row
Vivo Opportunity Cayman, LLC Common Stock, par value $0.0001 per share0.3549,487.0009/30/2025 Filed 2025-11-14SCHEDULE 13GOpen filing 0001213900-25-111134 Dispute this row
TANG CAPITAL MANAGEMENT, LLC Common Stock, par value $0.0001 per share9.9917,176,510.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001214659-25-016681 Dispute this row
KEVIN TANG Common Stock, par value $0.0001 per share9.9917,176,510.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001214659-25-016681 Dispute this row
TANG CAPITAL PARTNERS, LP Common Stock, par value $0.0001 per share5.9810,274,944.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001214659-25-016681 Dispute this row
TANG CAPITAL PARTNERS INTERNATIONAL, LP Common Stock, par value $0.0001 per share3.245,568,566.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001214659-25-016681 Dispute this row
TANG CAPITAL PARTNERS III, INC Common Stock, par value $0.0001 per share0.58999,750.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001214659-25-016681 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,039,221 filings read, dated 2004-06-14 to 2026-11-13: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202240,015
2023199,811
2024132,910
2025235,520
2026254,026

Filings made before the SEC required XML are listed, not extracted.

Back to Compass Therapeutics, Inc.